Via its affiliate CB Biotechnology, US-headquartered Future Pak will purchase shares in Theratechnologies for $3.01 each plus a contingent value right (CVR) of $1.19 on the achievement of future ...

The UK’s Labour Government has revealed its ’10-Year Health Plan’ for the country’s National Health Service (NHS). Speaking at a community health centre in London, Health Secretary Wes Streeting ...

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.

Lynozyfic has the potential to be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.

Ligand Pharmaceuticals’ subsidiary LNHC has concluded its merger with CHRO Merger Sub to form a new entity, Pelthos Therapeutics.

The U.S. Food and Drug Administration’s (FDA’s) evolving guidance on Computer Software Assurance and AI/ML-Based Software feels like it’s changing faster than you can read it. They’re emphasizing ...

A new podcast from industry experts MarketScan explains why social determinants of health are critical to patient care.

The UK Government is pushing for a single, unified digital patient record within the NHS, but experts have shared cybersecurity concerns.

Dizal has received FDA approval for Zegfrovy to treat adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

Sanofi is to invest up to $25m in Adagene, which will enable the latter to fund its R&D efforts, including clinical development of muzastotug.

US President Donald Trump’s One Big Beautiful Bill Act (H.R. 1) has narrowly passed after US Vice President JD Vance broke a 50-50 deadlock in the US Senate.